These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6430323)

  • 1. The effect of cyclandelate on cholesterol synthesis.
    Middleton B; Middleton A; Miciak A; Edwards E; Whitten B; Bell GD; White DA
    Br J Clin Pract Suppl; 1984; 34():43-50. PubMed ID: 6430323
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo inhibition of hepatic lipogenesis in the rat by cyclandelate (3,3',5-trimethylcyclohexanylmandelate).
    Middleton A; White DA; Bell GD; Middleton B
    Biochem Pharmacol; 1983 Oct; 32(20):3079-83. PubMed ID: 6639676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of hepatic S-3-hydroxy-3-methylglutaryl-CoA reductase by 3,3,5-trimethylcyclohexanol and its mandelic acid ester, cyclandelate.
    Middleton B; Middleton A; Miciak A; White DA; Bell GD
    Biochem Pharmacol; 1983 Feb; 32(4):649-51. PubMed ID: 6681959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of aldose reductase from rat nervous tissue by metabolites of cyclandelate.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():31-3. PubMed ID: 6430320
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of acyl coenzyme A: cholesterol acyl transferase by trimethylcyclohexanylmandelate (cyclandelate).
    Heffron F; Middleton B; White DA
    Biochem Pharmacol; 1990 Feb; 39(3):575-80. PubMed ID: 2306268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphodiesterase.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():20-5. PubMed ID: 6331483
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of cholesterol synthesis in the liver and mammary gland of the lactating rat.
    Gibbons GF; Pullinger CR; Munday MR; Williamson DH
    Biochem J; 1983 Jun; 212(3):843-8. PubMed ID: 6683964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 9. Benefits of cyclandelate in the treatment of disorders of ageing.
    Le Poncin-Lafitte M
    Br J Clin Pract Suppl; 1984; 34():58-61. PubMed ID: 6430325
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclandelate. An inhibitor of cholesterol esterification.
    Middleton B; Cacciaguerra F; White D
    Drugs; 1987; 33 Suppl 2():75-9. PubMed ID: 3622309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative effect of cyclandelate and papaverine on the cerebral circulation of the rabbit].
    Dumery JP
    Nouv Presse Med; 1976 Oct; 5(32):2081. PubMed ID: 980735
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclandelate and a number of its metabolites inhibit discocyte-echinocyte transformations of human erythrocytes.
    Van den Hoven WE; Hall DW; Burns JW
    Br J Clin Pract Suppl; 1984; 34():26-30. PubMed ID: 6430318
    [No Abstract]   [Full Text] [Related]  

  • 15. Mode of action of terbufibrol (INN) a hypolipidemic agent on rat liver sterol synthesis.
    Löser R; Schliack M; Moreth W
    Artery; 1982; 10(3):180-92. PubMed ID: 7201785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of cyclandelate vaso-active properties by the measure of the ear-retina time in the rabbit (author's transl)].
    Andermann C; Andermann G; Ehinger C
    Ann Pharm Fr; 1980; 38(3):253-60. PubMed ID: 7425477
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Endo A; Tsujita Y; Kuroda M; Tanzawa K
    Eur J Biochem; 1977 Jul; 77(1):31-6. PubMed ID: 908337
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
    Yamamoto A; Itoh S; Hoshi K; Ichihara K
    Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biphasic effect of exogenous oleate on the rate of cholesterol biosynthesis by rat hepatocytes.
    Pullinger CR; Gibbons GF
    Biochem Biophys Res Commun; 1981 Mar; 99(1):37-43. PubMed ID: 7236270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.